Andrea Bonetto

List of Publications by Year
in descending order

59 papers	3,171 citations	201385 27 h-index	155451 55 g-index
62 all docs	62 docs citations	62 times ranked	3379 citing authors

#	Article	IF	Citations
1	The Mitochondria-Targeting Agent MitoQ Improves Muscle Atrophy, Weakness and Oxidative Metabolism in C26 Tumor-Bearing Mice. Frontiers in Cell and Developmental Biology, 2022, 10, 861622.	1.8	15
2	Postoperative consequences of cancer cachexia after head and neck free flap reconstruction. Head and Neck, 2022, , .	0.9	2
3	Skeletal Muscle Indexâ€™s Impact on Discharge Disposition After Head and Neck Cancer Free Flap Reconstruction. Otolaryngology - Head and Neck Surgery, 2021, 165, 59-68.	1.1	11
4	Sarcopenia is associated with blood transfusions in head and neck cancer free flap surgery. Laryngoscope Investigative Otolaryngology, 2021, 6, 200-210.	0.6	10
5	Reduced rDNA transcription diminishes skeletal muscle ribosomal capacity and protein synthesis in cancer cachexia. FASEB Journal, 2021, 35, e21335.	0.2	20
6	Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments. Cells, 2021, 10, 516.	1.8	14
7	MC38 Tumors Induce Musculoskeletal Defects in Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 1486.	1.8	17
8	Targeting Mitochondria by SS-31 Ameliorates the Whole Body Energy Status in Cancer- and Chemotherapy-Induced Cachexia. Cancers, 2021, 13, 850.	1.7	32
9	Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. Journal of Experimental Medicine, 2021, 218, .	4.2	89
10	Role of myokines and osteokines in cancer cachexia. Experimental Biology and Medicine, 2021, 246, 2118-2127.	1.1	20
11	Abstract 969: PKC-theta modulates myosteatosis, muscle function, atrophy, and survival in murine pancreatic ductal adenocarcinoma. , 2021, , .		0
12	Metabolic Biomarkers for the Early Detection of Cancer Cachexia. Frontiers in Cell and Developmental Biology, 2021, 9, 720096.	1.8	11
13	Non-bone metastatic cancers promote osteocyte-induced bone destruction. Cancer Letters, 2021, 520, 80-90.	3.2	13
14	Muscle weakness caused by cancer and chemotherapy is associated with loss of motor unit connectivity. American Journal of Cancer Research, 2021, 11, 2990-3001.	1.4	4
15	Osteocytes and Cancer. Current Osteoporosis Reports, 2021, 19, 616-625.	1.5	9
16	ACVR2B antagonism as a countermeasure to multiâ€organ perturbations in metastatic colorectal cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 1779-1798.	2.9	26
17	HCT116 colorectal liver metastases exacerbate muscle wasting in a mouse model for the study of colorectal cancer cachexia. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	24
18	Impact of Sarcopenia on Outcomes of Autologous Head and Neck Free Tissue Reconstruction. Journal of Reconstructive Microsurgery, 2020, 36, 369-378.	1.0	28

#	Article	IF	Citations
19	Treatment With Treprostinil and Metformin Normalizes Hyperglycemia and Improves Cardiac Function in Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1543-1558.	1.1	20
20	Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia. JCI Insight, 2020, 5, .	2.3	20
21	RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non-Metastatic Ovarian Cancer in Mice. Journal of Bone and Mineral Research, 2020, 37, 381-396.	3.1	13
22	Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) R47H Variant Causes Distinct Age- and Sex-Dependent Musculoskeletal Alterations in Mice. Journal of Bone and Mineral Research, 2020, 37, 1366-1381.	3.1	10
23	Transcriptome Profiling Reveals Matrisome Alteration as a Key Feature of Ovarian Cancer Progression. Cancers, 2019, 11, 1513.	1.7	34
24	Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia. Cancers, 2019, 11, 1222.	1.7	12
25	Molecular Mechanisms Responsible for the Rescue Effects of Pamidronate on Muscle Atrophy in Pediatric Burn Patients. Frontiers in Endocrinology, 2019, 10, 543.	1.5	26
26	Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 140-154.	2.9	148
27	Chronic Treatment with Multi-Kinase Inhibitors Causes Differential Toxicities on Skeletal and Cardiac Muscles. Cancers, 2019, 11, 571.	1.7	25
28	Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice. Bone, 2019, 124, 89-102.	1.4	26
29	PDK4 drives metabolic alterations and muscle atrophy in cancer cachexia. FASEB Journal, 2019, 33, 7778-7790.	0.2	46
30	Bisphosphonate Treatment Ameliorates Chemotherapy-Induced Bone and Muscle Abnormalities in Young Mice. Frontiers in Endocrinology, 2019, 10, 809.	1.5	36
31	Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Current Opinion in Supportive and Palliative Care, 2018, 12, 420-426.	0.5	108
32	Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 685-700.	2.9	74
33	ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Scientific Reports, 2017, 7, 14470.	1.6	44
34	Post-translationally modified muscle-specific ubiquitin ligases as circulating biomarkers in experimental cancer cachexia. American Journal of Cancer Research, 2017, 7, 1948-1958.	1.4	2
35	Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs. Oncotarget, 2016, 7, 43442-43460.	0.8	145
36	Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways. Frontiers in Physiology, 2016, 7, 472.	1.3	138

#	Article	IF	Citations
37	Effect of the specific proteasome inhibitor bortezomib on cancerâ€related muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 345-354.	2.9	58
38	The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia. Journal of Visualized Experiments, 2016, , .	0.2	75
39	STAT3 in the systemic inflammation of cancer cachexia. Seminars in Cell and Developmental Biology, 2016, 54, 28-41.	2.3	171
40	Differential Bone Loss in Mouse Models of Colon Cancer Cachexia. Frontiers in Physiology, 2016, 7, 679.	1.3	44
41	Assessment of muscle mass and strength in mice. BoneKEy Reports, 2015, 4, 732.	2.7	93
42	Glutamine and Myostatin Expression in Muscle Wasting. , 2015, , 513-526.		1
43	Mu<scp>RF</scp>â€1 and pâ€<scp>GSK</scp>3Î² expression in muscle atrophy of cirrhosis. Liver International, 2013, 33, 714-721.	1.9	33
44	Early changes of muscle insulinâ€like growth factorâ€1 and myostatin gene expression in gastric cancer patients. Muscle and Nerve, 2013, 48, 387-392.	1.0	26
45	JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. American Journal of Physiology - Endocrinology and Metabolism, 2012, 303, E410-E421.	1.8	318
46	Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 199-211.	2.9	58
47	Changes in Myostatin Signaling in Non-Weight-Losing Cancer Patients. Annals of Surgical Oncology, 2012, 19, 1350-1356.	0.7	68
48	STAT3 Activation in Skeletal Muscle Links Muscle Wasting and the Acute Phase Response in Cancer Cachexia. PLoS ONE, 2011, 6, e22538.	1.1	284
49	Î²-hydroxy-Î²-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia. International Journal of Oncology, 2011, 38, 713-20.	1.4	43
50	Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-Î±. Amino Acids, 2011, 40, 585-594.	1.2	38
51	Muscle atrophy in experimental cancer cachexia: Is the IGFâ€1 signaling pathway involved?. International Journal of Cancer, 2010, 127, 1706-1717.	2.3	94
52	Therapeutic Potential of Proteasome Inhibition in Duchenne and Becker Muscular Dystrophies. American Journal of Pathology, 2010, 176, 1863-1877.	1.9	71
53	Are antioxidants useful for treating skeletal muscle atrophy?. Free Radical Biology and Medicine, 2009, 47, 906-916.	1.3	44
54	The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 817-828.	1.1	14

#	Article	IF	Citations
55	Deacetylase Inhibitors Modulate the Myostatin/Follistatin Axis without Improving Cachexia in Tumor-Bearing Mice. Current Cancer Drug Targets, 2009, 9, 608-616.	0.8	61
56	Muscle myostatin signalling is enhanced in experimental cancer cachexia. European Journal of Clinical Investigation, 2008, 38, 531-538.	1.7	150
57	New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'. Asia Pacific Journal of Clinical Nutrition, 2008, 17 Suppl 1, 387-90.	0.3	4
58	Nutritional Support in Cancer. Current Nutrition and Food Science, 2007, 3, 242-248.	0.3	0
59	IGF-1 is downregulated in experimental cancer cachexia. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 291, R674-R683.	0.9	149